Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
INO's Cash-to-Debt is ranked higher than
96% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. INO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.17  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
INO's Equity-to-Asset is ranked higher than
58% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. INO: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
INO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.78 Max: 0.93
Current: 0.71
0.49
0.93
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
95% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 1.19
Beneish M-Score: -1.75
WACC vs ROIC
16.58%
-343.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -215.55
INO's Operating Margin % is ranked lower than
59% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. INO: -215.55 )
Ranked among companies with meaningful Operating Margin % only.
INO' s Operating Margin % Range Over the Past 10 Years
Min: -651  Med: -266.85 Max: -84.5
Current: -215.55
-651
-84.5
Net Margin % -208.49
INO's Net Margin % is ranked lower than
60% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. INO: -208.49 )
Ranked among companies with meaningful Net Margin % only.
INO' s Net Margin % Range Over the Past 10 Years
Min: -618.02  Med: -277.15 Max: -71.94
Current: -208.49
-618.02
-71.94
ROE % -47.34
INO's ROE % is ranked lower than
55% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. INO: -47.34 )
Ranked among companies with meaningful ROE % only.
INO' s ROE % Range Over the Past 10 Years
Min: -152.12  Med: -46.91 Max: -20.35
Current: -47.34
-152.12
-20.35
ROA % -36.97
INO's ROA % is ranked lower than
53% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. INO: -36.97 )
Ranked among companies with meaningful ROA % only.
INO' s ROA % Range Over the Past 10 Years
Min: -98.97  Med: -32.88 Max: -16.89
Current: -36.97
-98.97
-16.89
ROC (Joel Greenblatt) % -898.65
INO's ROC (Joel Greenblatt) % is ranked lower than
58% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. INO: -898.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7552.88  Med: -3809.2 Max: -576.69
Current: -898.65
-7552.88
-576.69
3-Year Revenue Growth Rate 18.30
INO's 3-Year Revenue Growth Rate is ranked higher than
70% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INO: 18.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.2  Med: 3.5 Max: 163.7
Current: 18.3
-81.2
163.7
3-Year EBITDA Growth Rate 38.10
INO's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. INO: 38.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.1  Med: -16.6 Max: 38.1
Current: 38.1
-34.1
38.1
3-Year EPS without NRI Growth Rate -10.90
INO's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. INO: -10.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.2  Med: -10.5 Max: 27.9
Current: -10.9
-28.2
27.9
GuruFocus has detected 4 Warning Signs with Inovio Pharmaceuticals Inc $INO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INO's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

INO Guru Trades in Q4 2015

Jim Simons 392,781 sh (New)
Joel Greenblatt 37,123 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2016

INO Guru Trades in Q1 2016

Paul Tudor Jones 50,305 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
» More
Q2 2016

INO Guru Trades in Q2 2016

Paul Tudor Jones 26,801 sh (-46.72%)
» More
Q3 2016

INO Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:MYOK, NAS:OMER, OTCPK:SPHDF, NAS:MRUS, OTCPK:SNBIF, NAS:CRBP, NAS:CERS, NAS:CRVS, NAS:PACB, NAS:MCRB, OTCPK:ABVC, NAS:CRIS, NAS:CLDX, NAS:MACK, NAS:CARA, NAS:AGEN, NAS:RARX, NAS:NSTG, NAS:OTIC, NAS:AUPH » details
Traded in other countries:GBMB.Germany,
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Inovio Pharmaceuticals is a biotechnology company that develops active DNA immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Inovio aims to advance products through to commercialization. The company uses acquisitions, strategic alliances, and licensing agreements to fund the development of its products.

Ratios

vs
industry
vs
history
PB Ratio 3.63
INO's PB Ratio is ranked higher than
51% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. INO: 3.63 )
Ranked among companies with meaningful PB Ratio only.
INO' s PB Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.67 Max: 13.19
Current: 3.63
0.38
13.19
PS Ratio 12.53
INO's PS Ratio is ranked higher than
51% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. INO: 12.53 )
Ranked among companies with meaningful PS Ratio only.
INO' s PS Ratio Range Over the Past 10 Years
Min: 1.5  Med: 15.43 Max: 74.29
Current: 12.53
1.5
74.29
EV-to-EBIT -4.51
INO's EV-to-EBIT is ranked lower than
99.99% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. INO: -4.51 )
Ranked among companies with meaningful EV-to-EBIT only.
INO' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.5  Med: -5.15 Max: -0.3
Current: -4.51
-30.5
-0.3
EV-to-EBITDA -4.70
INO's EV-to-EBITDA is ranked lower than
99.99% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. INO: -4.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
INO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.3  Med: -5.6 Max: -0.3
Current: -4.7
-33.3
-0.3
Current Ratio 2.84
INO's Current Ratio is ranked lower than
64% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. INO: 2.84 )
Ranked among companies with meaningful Current Ratio only.
INO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.56 Max: 11.87
Current: 2.84
1.04
11.87
Quick Ratio 2.84
INO's Quick Ratio is ranked lower than
60% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INO: 2.84 )
Ranked among companies with meaningful Quick Ratio only.
INO' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.56 Max: 11.87
Current: 2.84
1.04
11.87
Days Sales Outstanding 163.28
INO's Days Sales Outstanding is ranked lower than
86% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. INO: 163.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
INO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.24  Med: 80.05 Max: 163.28
Current: 163.28
6.24
163.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.10
INO's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INO: -12.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.3  Med: -30.8 Max: -12
Current: -12.1
-45.3
-12

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.29
INO's Price-to-Net-Cash is ranked lower than
99.99% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. INO: 8.29 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.18  Med: 7.06 Max: 36.25
Current: 8.29
2.18
36.25
Price-to-Net-Current-Asset-Value 6.05
INO's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. INO: 6.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.99  Med: 6.94 Max: 26.98
Current: 6.05
1.99
26.98
Price-to-Tangible-Book 4.26
INO's Price-to-Tangible-Book is ranked higher than
52% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. INO: 4.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.92  Med: 4.99 Max: 16.64
Current: 4.26
1.92
16.64
Price-to-Median-PS-Value 0.81
INO's Price-to-Median-PS-Value is ranked lower than
99.99% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. INO: 0.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.07 Max: 54.05
Current: 0.81
0.28
54.05
Earnings Yield (Greenblatt) % -22.17
INO's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. INO: -22.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.15  Med: 0 Max: 0
Current: -22.17
-23.15
0

More Statistics

Revenue (TTM) (Mil) $35.37
EPS (TTM) $ -1.01
Beta1.89
Short Percentage of Float15.83%
52-Week Range $5.83 - 11.69
Shares Outstanding (Mil)74.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27 28 55
EPS ($) -1.26 -1.30 -0.96
EPS without NRI ($) -1.26 -1.30 -0.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 

More From Other Websites
INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Mar 24 2017
INOVIO PHARMACEUTICALS, INC. Financials Mar 21 2017
George Bickerstaff Elected to Inovio’s Board of Directors Mar 21 2017
Video-Taking Immunotherapy to the Next Level for Inovio Pharmaceuticals, Inc. Mar 20 2017
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017 Mar 17 2017
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : March... Mar 17 2017
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline Mar 16 2017
Inovio Pharma downgraded by Piper Jaffray Mar 16 2017
Inovio reports 4Q loss Mar 15 2017
Inovio reports 4Q loss Mar 15 2017
Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results Mar 15 2017
INOVIO PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 15 2017
Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts Mar 13 2017
4 Most Shorted Stocks Reporting Earnings This Week Mar 13 2017
INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 09 2017
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15,... Mar 09 2017
Inovio (INO): What's in the Cards this Earnings Season? Mar 06 2017
Inovio Universal Cancer Drug Shows High Potential Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)